Evaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis.
10.7518/hxkq.2024.2024241
- Author:
Dandan LI
1
;
Zhujun YU
1
;
Cheng NIE
1
;
Zixin ZOU
1
;
Jianli WANG
1
Author Information
1. State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
bisphosphonate;
chronic nonbacterial osteomyelitis;
drug factor;
efficacy
- MeSH:
Osteomyelitis/drug therapy*;
Humans;
Diphosphonates/administration & dosage*;
Chronic Disease;
Bone Density Conservation Agents/administration & dosage*;
Female;
Pamidronate;
Middle Aged;
Male
- From:
West China Journal of Stomatology
2025;43(1):98-105
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:This study aimed to analyze the influence of drug factors on the efficacy of bisphosphonate for chronic nonbacterial osteomyelitis to provide a reference for clinical treatment and promote clinical rational drug use by evaluation of effectiveness and safety of bisphosphonate treatment of chronic nonbacterial osteomyelitis.
METHODS:Literature on the treatment of chronic nonbacterial osteomyelitis by using bisphosphonate was collected and analyzed from PubMed, Medline, Embase, Cochrane, ISI Web of Knowledge, CNKI, VIP, and Wanfang databases.
RESULTS:A total of 489 cases were collected, with an average complete response rate of clinical presentation, laboratory tests and imaging findings of 80.37%, 80.56% and 79.22%, respectively. Except for opadronate, risedronate, ibandronate, pamidronate, alendronate, neidronate and zoledronate showed good efficacy, and the average complete response rates were 100%, 100%, 81.64%, 87.50%, 69.23% and 69.23%, respectively.The study found that in the pamidronate group, the average complete response rate of 0.5-1 mg/kg (maximum single dose≤60 mg) subgroup and the frequency of administration once every 3 months subgroup were better than other subgroups.
CONCLUSIONS:Bisphosphonate could be used to treat chronic nonbacterial osteomyelitis, which of efficacy were affected by different drug types, dose and frequency of administration. The optimal dose and frequency of administration of pamidronate were 0.5-1 mg/kg (maximum single dose≤60 mg) and once every 3 months, respectively.
